세계의 포도막염 치료 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Uveitis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,876,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,043,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,695,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 포도막염 치료 시장 규모는 2025년에 8억 4,820만 달러에 달하고, 2025년-2032년의 예측 기간에 7.3%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 2032년에는 13억 8,900만 달러에 달할 것으로 예측되고 있습니다.

포도막염은 포도막에 영향을 미치는 염증성 질환군으로, 방치하면 시력 저하로 이어질 수 있습니다. 포도막염 치료 시장에는 염증을 억제하고, 면역 반응을 조절하고, 합병증을 예방하는 것을 목표로 하는 부신피질 스테로이드, 면역억제제, 생물학적 제제 및 기타 치료법이 포함됩니다. 자가면역 질환의 유병률 증가, 눈 건강에 대한 의식 증가, 치료 방법의 진보가 시장 성장을 가속하고 있습니다. 병원, 안과 클리닉, 전문 안과 센터는 포도막염 치료 솔루션의 주요 최종 사용자입니다.

세계의 포도막염 치료 시장은 포도막염과 관련된 류마티스 관절염 및 강직성 척추염과 같은 자가면역 질환의 이환율 증가와 같은 몇 가지 중요한 요인들에 의해 추진되고 있습니다. 또한 TNFα 억제제와 IL-6 억제제를 포함한 생물학적 제제의 진보로 치료 효과가 향상되고 재발률이 저하되고 있습니다. 안과 연구에 대한 투자 확대와 헬스케어 지출 증가도 시장 확대에 크게 기여하고 있습니다. 또한, 포도막염에 걸리기 쉬운 노년 인구 증가는 효과적인 치료 옵션에 대한 수요를 촉진할 것으로 예상됩니다.

포도막염 치료 시장은 표적 치료제의 기술 혁신, 유전자 기반 치료법에 대한 연구 증가 및 질병의 조기 발견에서 AI의 통합으로 큰 성장 기회를 제공합니다. 장시간 작용형 주사제나 서방형 제제의 개발에 의해 환자의 복약 준수가 향상되어 빈번 투여의 부담이 경감될 것으로 기대됩니다. 또한, 원격 의료 및 디지털 건강 플랫폼의 확장은 특히 원격지에서 포도막염 전문의에 대한 환자 접근을 개선하고 있습니다. 제약기업과 연구기관의 전략적 제휴도 새로운 치료법의 개발을 촉진하고 있습니다.

본 보고서에서는 세계 포도막염 치료 시장에 대해 조사했으며, 치료별, 질환별, 원인별, 유통채널별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 주요 시장 동향

제4장 중요 성공 요인

제5장 시장 배경

• 거시경제 요인
• 예측 요인- 관련성과 영향
• 동향

제6장 COVID-19 위기- 영향 평가

제7장 세계 시장 수요 전망, 2019년-2032년

• 과거 시장 매출(100만 달러) 분석, 2019년-2024년
• 현재 및 장래 시장 매출(100만 달러) 예측, 2025년-2032년

제8장 세계 시장 전망, 치료별, 2019년-2032년

• 과거 시장 규모(100만 달러) 분석, 치료별, 2019년-2024년
• 현재 및 장래 시장 규모(100만 달러) 분석과 예측, 치료별, 2025년-2032년
• 치료별 시장의 매력 분석

제9장 세계 시장 전망, 질병별, 2019년-2032년

• 과거 시장 규모(100만 달러) 분석, 질병별, 2019년-2024년
• 현재 및 장래 시장 규모(100만 달러) 분석과 예측, 질환별, 2025년-2032년
• 질병별 시장의 매력 분석

제10장 세계 시장 전망, 원인별, 2019년-2032년

• 과거 시장 규모(100만 달러) 분석, 원인별, 2019년-2024년
• 현재 및 장래 시장 규모(100만 달러) 분석과 예측, 원인별, 2025년-2032년
• 원인별 시장의 매력 분석

제11장 세계 시장 전망, 유통채널별, 2019년-2032년

• 과거 시장 규모(100만 달러) 분석, 유통채널별, 2019년-2024년
• 현재 및 장래 시장 규모(100만 달러) 분석과 예측, 유통 채널별, 2025년-2032년
• 유통 채널별 시장의 매력 분석

제12장 세계 시장 전망, 지역별, 2019년-2032년

• 과거 시장 규모(100만 달러) 분석, 지역별, 2019년-2024년
• 현재 및 장래 시장 규모(100만 달러) 분석과 예측, 지역별, 2025년-2032년
• 지역별 시장의 매력 분석

제13장 북미 시장 전망, 2019년-2032년

제14장 라틴아메리카 시장 전망, 2019년-2032년

제15장 유럽 시장 전망, 2019년-2032년

제16장 남아시아 시장 전망, 2019년-2032년

제17장 동아시아 시장 전망, 2019년-2032년

제18장 오세아니아 시장 전망, 2019년-2032년

제19장 중동 및 아프리카 시장 전망, 2019년-2032년

제20장 시장 구조 분석

제21장 경쟁 분석

• 경쟁 대시보드
• 브랜딩 및 프로모션 전략
• 주요 개발 분석
• 경쟁의 상세
  • Allergan, Inc
  • Novartis AG
  • Bausch Health Inc.
  • AbbVie Inc.
  • Tarsier Pharma
  • EyeGate Pharmaceuticals, Inc.
  • Alimera Science Inc
  • Eyepoint Pharmaceutical
  • Santen Pharmaceuticals

제22장 사용된 전제조건과 약어

제23장 조사 방법

SHW

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for uveitis treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global uveitis treatment market from 2025 to 2032.

Key Insights:

• Uveitis Treatment Market Size (2025E): USD 848.2 Million
• Projected Market Value (2032F): USD 1,389.0 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 7.3%

Uveitis Treatment Market - Report Scope:

Uveitis is a group of inflammatory conditions affecting the uvea, which can lead to vision loss if left untreated. The market for uveitis treatment includes corticosteroids, immunosuppressants, biologics, and other therapeutic approaches aimed at reducing inflammation, controlling immune responses, and preventing complications. The increasing prevalence of autoimmune diseases, growing awareness regarding eye health, and advancements in treatment modalities are fueling market growth. Hospitals, ophthalmology clinics, and specialty eye centers are the key end-users of uveitis treatment solutions.

Market Growth Drivers:

The global uveitis treatment market is propelled by several key factors, including the rising incidence of autoimmune disorders such as rheumatoid arthritis and ankylosing spondylitis, which are linked to uveitis. Additionally, advancements in biologic therapies, including TNF-alpha inhibitors and IL-6 inhibitors, are enhancing treatment efficacy and reducing recurrence rates. Growing investment in ophthalmic research and increasing healthcare expenditure are also major contributors to market expansion. Moreover, the growing geriatric population, which is more susceptible to uveitis, is expected to drive demand for effective treatment options.

Market Restraints:

Despite promising growth prospects, the uveitis treatment market faces challenges related to high treatment costs, limited availability of advanced biologic therapies in emerging economies, and potential side effects associated with long-term corticosteroid use. Regulatory hurdles for new drug approvals and the complexity of uveitis diagnosis further hinder market penetration. Additionally, the lack of awareness and delayed treatment can result in irreversible vision damage, impacting market growth.

Market Opportunities:

The uveitis treatment market presents significant growth opportunities driven by innovations in targeted therapies, increasing research in gene-based treatments, and the integration of AI in early disease detection. The development of long-acting injectables and sustained-release drug formulations is expected to enhance patient adherence and reduce the burden of frequent dosing. Furthermore, the expansion of telemedicine and digital health platforms is improving patient access to uveitis specialists, particularly in remote areas. Strategic collaborations between pharmaceutical companies and research institutions are also fostering the development of novel treatment options.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the uveitis treatment market globally?
• Which treatment modalities are gaining prominence in uveitis management?
• How are technological advancements reshaping the competitive landscape of the uveitis treatment market?
• Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global uveitis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global uveitis treatment market, including AbbVie Inc., Novartis AG, Pfizer Inc., and Santen Pharmaceutical Co., Ltd., focus on research and development, product innovation, and strategic collaborations to strengthen their market position. These companies are investing in biologic therapies, sustained-release drug formulations, and advanced diagnostic tools to improve treatment outcomes. Additionally, partnerships with healthcare providers and government initiatives for eye disease awareness are driving market expansion.

Key Companies Profiled:

• AbbVie Inc.
• Novartis AG
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch Health Companies Inc.
• Alimera Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Eyepoint Pharmaceuticals, Inc.
• UCB S.A.
• Johnson & Johnson

Key Segments Covered in Uveitis Treatment Industry Research

By Treatment:

• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Antibiotics
• Antivirals
• Antifungal
• Analgesics

Disease:

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

Cause:

• Infectious Uveitis
• Non-infectious Uveitis

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Treatment Adoption / Analysis
• 4.2. Disease Epidemiology
• 4.3. Pipeline Assessment
• 4.4. Patient Journey Analysis
• 4.5. PESTLE Analysis
• 4.6. Regulatory Scenario

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Retinal Disorder Treatment Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rise in Autoimmune Diseases
  • 5.2.2. Rise in Infectious Uveitis
  • 5.2.3. Treatment Adoption Rate
  • 5.2.4. Growing Number of Service Providers
  • 5.2.5. Rise in Infectious Illness Frequency in Developing Nations
  • 5.2.6. Mergers and Acquisitions
• 5.3. Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Treatment
  • 6.1.2. By Disease
  • 6.1.3. By Cause
  • 6.1.4. By Distribution Channel
  • 6.1.5. By Region
• 6.2. 2022 Market Scenario

7. Global Market Demand Outlook, 2019 - 2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019 - 2024
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2025 - 2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Outlook, 2019 - 2032

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2019 - 2024
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2025 - 2032
  • 8.3.1. Corticosteroids
  • 8.3.2. Immunosuppressant
  • 8.3.3. Monoclonal Antibodies
  • 8.3.4. Cycloplegic Agents
  • 8.3.5. Antibiotics
  • 8.3.6. Antivirals
  • 8.3.7. Antifungal
  • 8.3.8. Analgesics
• 8.4. Market Attractiveness Analysis By Treatment

9. Global Market Outlook, 2019 - 2032

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Disease, 2019 - 2024
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease, 2025 - 2032
  • 9.3.1. Anterior Uveitis
  • 9.3.2. Posterior Uveitis
  • 9.3.3. Intermediate Uveitis
  • 9.3.4. Panuveitis
• 9.4. Market Attractiveness Analysis By Disease

10. Global Market Outlook, 2019 - 2032

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Cause, 2019 - 2024
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Cause, 2025 - 2032
  • 10.3.1. Infectious Uveitis
  • 10.3.2. Non-infectious Uveitis
• 10.4. Market Attractiveness Analysis By Cause

11. Global Market Analysis Outlook, 2019 - 2032

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019 - 2024
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025 - 2032
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
  • 11.3.4. Drug Stores
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Outlook, 2019 - 2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019 - 2024
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025 - 2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Market Outlook, 2019 - 2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Treatment
  • 13.3.3. By Disease
  • 13.3.4. By Cause
  • 13.3.5. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Treatment
  • 13.4.3. By Disease
  • 13.4.4. By Cause
  • 13.4.5. By Distribution Channel
• 13.5. Country Level Analysis & Forecast
  • 13.5.1. U.S. Market Analysis
    • 13.5.1.1. . Introduction
    • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.1.2.1. By Treatment
      • 13.5.1.2.2. By Disease
      • 13.5.1.2.3. By Cause
      • 13.5.1.2.4. By Distribution Channel
  • 13.5.2. Canada Market Analysis
    • 13.5.2.1. Introduction
    • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.2.2.1. By Treatment
      • 13.5.2.2.2. By Disease
      • 13.5.2.2.3. By Cause
      • 13.5.2.2.4. By Distribution Channel
• 13.6. Market Trends
• 13.7. Key Market Participants - Intensity Mapping
• 13.8. Drivers and Restraints - Impact Analysis

14. Latin America Market Outlook, 2019 - 2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
      • 14.3.1.4.1. By Treatment
      • 14.3.1.4.2. By Disease
      • 14.3.1.4.3. By Cause
      • 14.3.1.4.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Treatment
  • 14.4.3. By Distribution Channel
• 14.5. Country Level Analysis & Forecast
  • 14.5.1. Brazil Market Analysis
    • 14.5.1.1. . Introduction
    • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.1.2.1. By Treatment
      • 14.5.1.2.2. By Disease
      • 14.5.1.2.3. By Cause
      • 14.5.1.2.4. By Distribution Channel
  • 14.5.2. Mexico Market Analysis
    • 14.5.2.1. Introduction
    • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.2.2.1. By Treatment
      • 14.5.2.2.2. By Disease
      • 14.5.2.2.3. By Cause
      • 14.5.2.2.4. By Distribution Channel
  • 14.5.3. Argentina Market Analysis
    • 14.5.3.1. Introduction
    • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.3.2.1. By Treatment
      • 14.5.3.2.2. By Disease
      • 14.5.3.2.3. By Cause
      • 14.5.3.2.4. By Distribution Channel
• 14.6. Market Trends
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Drivers and Restraints - Impact Analysis

15. Europe Market Outlook, 2019 - 2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. France
    • 15.3.1.3. Italy
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. Russia
    • 15.3.1.7. BENELUX
    • 15.3.1.8. Nordic Countries
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Treatment
  • 15.3.3. By Disease
  • 15.3.4. By Cause
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Treatment
  • 15.4.3. By Disease
  • 15.4.4. By Cause
  • 15.4.5. By Distribution Channel
• 15.5. Country Level Analysis & Forecast
  • 15.5.1. Germany Market Analysis
    • 15.5.1.1. . Introduction
    • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.1.2.1. By Treatment
      • 15.5.1.2.2. By Disease
      • 15.5.1.2.3. By Cause
      • 15.5.1.2.4. By Distribution Channel
  • 15.5.2. France Market Analysis
    • 15.5.2.1. Introduction
    • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.2.2.1. By Treatment
      • 15.5.2.2.2. By Disease
      • 15.5.2.2.3. By Cause
      • 15.5.2.2.4. By Distribution Channel
  • 15.5.3. Italy Market Analysis
    • 15.5.3.1. Introduction
    • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.3.2.1. By Treatment
      • 15.5.3.2.2. By Disease
      • 15.5.3.2.3. By Cause
      • 15.5.3.2.4. By Distribution Channel
  • 15.5.4. U.K. Market Analysis
    • 15.5.4.1. . Introduction
    • 15.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.4.2.1. By Treatment
      • 15.5.4.2.2. By Disease
      • 15.5.4.2.3. By Cause
      • 15.5.4.2.4. By Distribution Channel
  • 15.5.5. Spain Market Analysis
    • 15.5.5.1. . Introduction
    • 15.5.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.5.2.1. By Treatment
      • 15.5.5.2.2. By Disease
      • 15.5.5.2.3. By Cause
      • 15.5.5.2.4. By Distribution Channel
  • 15.5.6. Russia Market Analysis
    • 15.5.6.1. . Introduction
    • 15.5.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.6.2.1. By Treatment
      • 15.5.6.2.2. By Disease
      • 15.5.6.2.3. By Cause
      • 15.5.6.2.4. By Distribution Channel
  • 15.5.7. Nordic Countries Market Analysis
    • 15.5.7.1. . Introduction
    • 15.5.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.7.2.1. By Treatment
      • 15.5.7.2.2. By Disease
      • 15.5.7.2.3. By Cause
      • 15.5.7.2.4. By Distribution Channel
  • 15.5.8. BENELUX Market Analysis
    • 15.5.8.1. . Introduction
    • 15.5.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.8.2.1. By Treatment
      • 15.5.8.2.2. By Disease
      • 15.5.8.2.3. By Cause
      • 15.5.8.2.4. By Distribution Channel
• 15.6. Market Trends
• 15.7. Key Market Participants - Intensity Mapping
• 15.8. Drivers and Restraints - Impact Analysis

16. South Asia Market Outlook, 2019 - 2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Thailand
    • 16.3.1.3. Indonesia
    • 16.3.1.4. Malaysia
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Treatment
  • 16.3.3. By Disease
  • 16.3.4. By Cause
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Treatment
  • 16.4.3. By Disease
  • 16.4.4. By Cause
  • 16.4.5. By Distribution Channel
• 16.5. Country Level Analysis & Forecast
  • 16.5.1. India Market Analysis
    • 16.5.1.1. . Introduction
    • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.1.2.1. By Treatment
      • 16.5.1.2.2. By Disease
      • 16.5.1.2.3. By Cause
      • 16.5.1.2.4. By Distribution Channel
  • 16.5.2. Thailand Market Analysis
    • 16.5.2.1. . Introduction
    • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.2.2.1. By Treatment
      • 16.5.2.2.2. By Disease
      • 16.5.2.2.3. By Cause
      • 16.5.2.2.4. By Distribution Channel
  • 16.5.3. Indonesia Market Analysis
    • 16.5.3.1. Introduction
    • 16.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.3.2.1. By Treatment
      • 16.5.3.2.2. By Disease
      • 16.5.3.2.3. By Cause
      • 16.5.3.2.4. By Distribution Channel
  • 16.5.4. Malaysia Market Analysis
    • 16.5.4.1. Introduction
    • 16.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.4.2.1. By Treatment
      • 16.5.4.2.2. By Disease
      • 16.5.4.2.3. By Cause
      • 16.5.4.2.4. By Distribution Channel
• 16.6. Market Trends
• 16.7. Key Market Participants - Intensity Mapping
• 16.8. Drivers and Restraints - Impact Analysis

17. East Asia Market Outlook, 2019 - 2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Treatment
  • 17.3.3. By Disease
  • 17.3.4. By Cause
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Treatment
  • 17.4.3. By Disease
  • 17.4.4. By Cause
  • 17.4.5. By Distribution Channel
• 17.5. Country Level Analysis & Forecast
  • 17.5.1. China Market Analysis
    • 17.5.1.1. . Introduction
    • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.1.2.1. By Treatment
      • 17.5.1.2.2. By Disease
      • 17.5.1.2.3. By Cause
      • 17.5.1.2.4. By Distribution Channel
  • 17.5.2. Japan Market Analysis
    • 17.5.2.1. Introduction
    • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.2.2.1. By Treatment
      • 17.5.2.2.2. By Disease
      • 17.5.2.2.3. By Cause
      • 17.5.2.2.4. By Distribution Channel
  • 17.5.3. South Korea Market Analysis
    • 17.5.3.1. Introduction
    • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.3.2.1. By Treatment
      • 17.5.3.2.2. By Disease
      • 17.5.3.2.3. By Cause
      • 17.5.3.2.4. By Distribution Channel
• 17.6. Market Trends
• 17.7. Key Market Participants - Intensity Mapping
• 17.8. Drivers and Restraints - Impact Analysis

18. Oceania Market Outlook, 2019 - 2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Treatment
  • 18.3.3. By Disease
  • 18.3.4. By Cause
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Treatment
  • 18.4.3. By Disease
  • 18.4.4. By Cause
  • 18.4.5. By Distribution Channel
• 18.5. Country Level Analysis & Forecast
  • 18.5.1. Australia Market Analysis
    • 18.5.1.1. . Introduction
    • 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.5.1.2.1. By Treatment
      • 18.5.1.2.2. By Disease
      • 18.5.1.2.3. By Cause
      • 18.5.1.2.4. By Distribution Channel
  • 18.5.2. New Zealand Market Analysis
    • 18.5.2.1. Introduction
    • 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.5.2.2.1. By Treatment
      • 18.5.2.2.2. By Disease
      • 18.5.2.2.3. By Cause
      • 18.5.2.2.4. By Distribution Channel
• 18.6. Market Trends
• 18.7. Key Market Participants - Intensity Mapping
• 18.8. Drivers and Restraints - Impact Analysis

19. Middle East and Africa Market Outlook, 2019 - 2032

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019 - 2024
• 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkiye
    • 19.3.1.3. Northern Africa
    • 19.3.1.4. South Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Treatment
  • 19.3.3. By Disease
  • 19.3.4. By Cause
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Treatment
  • 19.4.3. By Disease
  • 19.4.4. By Cause
  • 19.4.5. By Distribution Channel
• 19.5. Country Level Analysis & Forecast
  • 19.5.1. GCC Countries Market Analysis
    • 19.5.1.1. . Introduction
    • 19.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.5.1.2.1. By Treatment
      • 19.5.1.2.2. By Disease
      • 19.5.1.2.3. By Cause
      • 19.5.1.2.4. By Distribution Channel
  • 19.5.2. Turkiye Market Analysis
    • 19.5.2.1. Introduction
    • 19.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.5.2.2.1. By Treatment
      • 19.5.2.2.2. By Disease
      • 19.5.2.2.3. By Cause
      • 19.5.2.2.4. By Distribution Channel
  • 19.5.3. Northern Africa Market Analysis
    • 19.5.3.1. Introduction
    • 19.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.5.3.2.1. By Treatment
      • 19.5.3.2.2. By Disease
      • 19.5.3.2.3. By Cause
      • 19.5.3.2.4. By Distribution Channel
  • 19.5.4. South Africa Market Analysis
    • 19.5.4.1. Introduction
    • 19.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.5.4.2.1. By Treatment
      • 19.5.4.2.2. By Disease
      • 19.5.4.2.3. By Cause
      • 19.5.4.2.4. By Distribution Channel
• 19.6. Market Trends
• 19.7. Key Market Participants - Intensity Mapping
• 19.8. Drivers and Restraints - Impact Analysis

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Branding and Promotional Strategies
• 21.3. Key Development Analysis
• 21.4. Competition Deep Dive
  • 21.4.1. Allergan, Inc
    • 21.4.1.1. Overview
    • 21.4.1.2. Product Portfolio
    • 21.4.1.3. Key Financials
    • 21.4.1.4. Sales Footprint
    • 21.4.1.5. Strategy Overview
      • 21.4.1.5.1. Marketing Strategy
      • 21.4.1.5.2. Product Strategy
      • 21.4.1.5.3. Channel Strategy
  • 21.4.2. Novartis AG
    • 21.4.2.1. Overview
    • 21.4.2.2. Product Portfolio
    • 21.4.2.3. Key Financials
    • 21.4.2.4. Sales Footprint
    • 21.4.2.5. Strategy Overview
      • 21.4.2.5.1. Marketing Strategy
      • 21.4.2.5.2. Product Strategy
      • 21.4.2.5.3. Channel Strategy
  • 21.4.3. Bausch Health Inc.
    • 21.4.3.1. Overview
    • 21.4.3.2. Product Portfolio
    • 21.4.3.3. Key Financials
    • 21.4.3.4. Sales Footprint
    • 21.4.3.5. Strategy Overview
      • 21.4.3.5.1. Marketing Strategy
      • 21.4.3.5.2. Product Strategy
      • 21.4.3.5.3. Channel Strategy
  • 21.4.4. AbbVie Inc.
    • 21.4.4.1. Overview
    • 21.4.4.2. Product Portfolio
    • 21.4.4.3. Key Financials
    • 21.4.4.4. Sales Footprint
    • 21.4.4.5. Strategy Overview
      • 21.4.4.5.1. Marketing Strategy
      • 21.4.4.5.2. Product Strategy
      • 21.4.4.5.3. Channel Strategy
  • 21.4.5. Tarsier Pharma
    • 21.4.5.1. Overview
    • 21.4.5.2. Product Portfolio
    • 21.4.5.3. Key Financials
    • 21.4.5.4. Sales Footprint
    • 21.4.5.5. Strategy Overview
      • 21.4.5.5.1. Marketing Strategy
      • 21.4.5.5.2. Product Strategy
      • 21.4.5.5.3. Channel Strategy
  • 21.4.6. EyeGate Pharmaceuticals, Inc.
    • 21.4.6.1. Overview
    • 21.4.6.2. Product Portfolio
    • 21.4.6.3. Key Financials
    • 21.4.6.4. Sales Footprint
    • 21.4.6.5. Strategy Overview
      • 21.4.6.5.1. Marketing Strategy
      • 21.4.6.5.2. Product Strategy
      • 21.4.6.5.3. Channel Strategy
  • 21.4.7. Alimera Science Inc
    • 21.4.7.1. Overview
    • 21.4.7.2. Product Portfolio
    • 21.4.7.3. Key Financials
    • 21.4.7.4. Sales Footprint
    • 21.4.7.5. Strategy Overview
      • 21.4.7.5.1. Marketing Strategy
      • 21.4.7.5.2. Product Strategy
      • 21.4.7.5.3. Channel Strategy
  • 21.4.8. Eyepoint Pharmaceutical
    • 21.4.8.1. Overview
    • 21.4.8.2. Product Portfolio
    • 21.4.8.3. Key Financials
    • 21.4.8.4. Sales Footprint
    • 21.4.8.5. Strategy Overview
      • 21.4.8.5.1. Marketing Strategy
      • 21.4.8.5.2. Product Strategy
      • 21.4.8.5.3. Channel Strategy
  • 21.4.9. Santen Pharmaceuticals
    • 21.4.9.1. Overview
    • 21.4.9.2. Product Portfolio
    • 21.4.9.3. Key Financials
    • 21.4.9.4. Sales Footprint
    • 21.4.9.5. Strategy Overview
      • 21.4.9.5.1. Marketing Strategy
      • 21.4.9.5.2. Product Strategy
      • 21.4.9.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료